Celgene sells psoriasis pill to Amgen for $13.4b, on way to Bristol merger – STAT

Amgen will buy the psoriasis pill Otezla from Celgene, which is selling it to remove an obstacle from its planned merger with Bristol-Myers Squibb.

https://www.statnews.com/2019/08/26/celgene-psoriasis-pill-amgen-bristol-merger/
STAT
This site is not involved in the creation of this post.

Share

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.